

Fujirebio strategically collaborates with Stanford Medicine to advance infectious disease research

05 June 2025 | News

To accelerate the adoption of ultra-sensitive immunoassays incorporating single molecule counting technology



Fujirebio, a leading innovator in in-vitro diagnostics, has announced a collaboration with Stanford Medicine, in the US, to advance research and innovation in the field of infectious disease testing.

This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio's Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide.

Infectious diseases remain one of the greatest global health challenges of our time," says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. "By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights. This collaboration underscores our shared vision to create a healthier, more resilient world."